Hexima Ltd · ASX:HXL
Hexima — Shareholder Meeting (November 2008)
40 slides from Hexima's shareholder meeting presentation, Nov 25, 2008
Slide 1: Annual General Meeting
Annual General Meeting Tuesday 25th November 2008, 11:00am RACV Club 483-501 Bourke Street Melbourne, Victoria
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation relate to the future, including forward looking statements relating to Hexima’s future expectations, beliefs, goals, plans, prospects, financial position and strategy. These forward looking statements involve known and unknown risks,
Slide 3: Annual General Meeting - CEO
Annual General Meeting 25th November 2008 Mr Joshua Hofheimer Chief Executive Officer
Slide 4: The Role for Hexima in the Agribusiness Growth Story
The Role for Hexima in the Agribusiness Growth Story • Continued demand for food, feed, fuel and fibre • Increasing agricultural productivity requires innovative technology • Hexima collaborates with global leader DuPont 4 Hexima Limited ©
Slide 5: Grain Stocks Remain at Record Lows
Grain Stocks Remain at Record Lows 35% 115 days inventory 30% 25% 20% Stocks to Use (%) 15% 62 days inventory 10% 5% 0% 5 Source: USDA, ABN Amro Morgans Hexima Limited ©
Slide 6: China & India – Share of Global Consumption
China & India – Share of Global Consumption India + China = 37% global population Kilograms of grain needed to produce 1 kilogram of beef 6-7 KG 1 KG 6 Source: OECD/FAO Hexima Limited ©
Slide 7: Solving Global Supply Constraints: Growth Opportunities for Agricultural Productivity
Solving Global Supply Constraints: Where are the Growth Opportunities for Agricultural Productivity? Conventional Transgenic Conventional Land Fertiliser Processing Technology 7 Hexima Limited ©
Slide 8: Huge Growth Opportunity: GM Crops Make Up Just 8% of World Crops
Huge Growth Opportunity: GM Crops Make Up Just 8% of the World’s 1.5 Billion Hectares of Crops $US billion Source: ISAAA 8 * Hans Kast, BASF Hexima Limited ©
Slide 9: Hexima is Well Funded and Able to Capitalise on Its Technology
Hexima is Well Funded and Able to Capitalise on Its Technology Hexima’s Technology Financial Strength • Diverse portfolio of technologies • Hexima Limited IPO August ‘07 • Fungal Resistance • A$40million • Insect Resistance • ~4 years cash remaining • Protein Delivery (MGEV) • Clear strategy of ensu
Slide 10: Options for Commercialising Technology
Options for Commercialising Technology Full Collaboration Maintain Independence High High Royalty Rates DuPont/ Hexima Resources at Risk ($, people) Size denotes Industry Model relative return Low Royalty Rates Internal & External Competition Early Stage Technology Sale Low Time to Revenue 10 Hexima
Slide 11: How Does the DuPont Agreement Deliver Value?
How Does the DuPont Agreement Deliver Value? ¥ Hexima is DuPont’s exclusive anti-fungal protein disease partner ¥ Hexima controls development in crops other than corn and soy ¥ Access to enabling technology ¥ Co-investment option to double returns “Both the stature of the deal partner and the charac
Slide 12: Value Creation and Capture is Clear
Value Creation and Capture is Clear Yield Improvement Hexima’s royalty is directly linked to the measurable benefits to farmers, NOT the price charged by DuPont Chemical Displacement Value of Trait Farmer’s Insurance to Farmer Share Trait Price Seed Provider Technology Provider Disease related yield
Slide 13: Value Emerges Before Revenue: Development Process
Value Emerges Before Revenue: Development Process 13 Hexima Limited ©
Slide 14: Proteinase Inhibitors, MGEV & Pipeline: Maximise Value
Proteinase Inhibitors, MGEV & Pipeline: Maximise Value by Balancing Resources, Risk and Time to Return Full Collaboration Maintain Independence High High Royalty Rates DuPont/ Hexima Resources at Risk ($, people) Size denotes relative return Low Time to Revenue 14 Hexima Limited ©
Slide 15: Financial Highlights
Financial Highlights CASH BALANCE $33.8 million (at 30 Sept 08) DEBT Zero ANNUAL SPEND $7-8 million projected investment p.a. Financial Results 2008 ($000) 2007 ($000) Revenue 1,156 542 Operating expenditure (6,597) (3,466) Net operating expenditure plus (3,030) (2,883) interest income 15 Hexima Lim
Slide 16: Summary
Summary ¥ Agricultural productivity requires technology ¥ Hexima: Hitting our milestones ¥ Execution of valuable commercialisation deal – a validation of Hexima’s technology ¥ Strong balance sheet 16 Hexima Limited ©
Slide 17: Discovery and Strategy
Annual General Meeting 25th November 2008 Professor Marilyn Anderson Senior Vice President Research and Discovery “Discovery and Strategy”
Slide 18: La Trobe University Biochemistry
La Trobe University Biochemistry 18 Hexima Limited ©
Slide 19: Discovery
Discovery Insecticidal molecules •Proteinase inhibitors •Cyclotides Antifungal molecules •Defensins MGEV 19 Hexima Limited ©
Slide 20: School of Molecular Sciences
School of Molecular Sciences Mass Spectrometry & Proteomics Facility 20 Hexima Limited ©
Slide 21: NMR Spectroscopy
NMR Spectroscopy Prof. David Craik – University of Queensland 21 Hexima Limited ©
Slide 22: Defensins – Ancient Immunity Proteins
Defensins – Ancient Immunity Proteins C N N N C C NaD1 Def A HBD-1 Plant Insect Mammalian 22 Hexima Limited ©
Slide 23: Defensins Kill Fusarium oxysporum-Fusarium wilt
Defensins Kill Fusarium oxysporum-Fusarium wilt 23 Hexima Limited ©
Slide 24: The NaD1 Defensin Kills Fungal Disease Pathogens
The NaD1 Defensin Kills Fungal Disease Pathogens With defensin No defensin 24 Hexima Limited ©
Slide 25: How do Defensins Kill Fungi?
How do Defensins Kill Fungi? Glycosylated proteins Cell Wall Plasma Membrane ROS nucleus Cytoplasm Death of fungus 25 Hexima Limited ©
Slide 26: NaD1 Makes Holes in Fungal Membranes
NaD1 Makes Holes in Fungal Membranes hyphae NaD1 – 2 mM • Defensin makes holes in fungal membranes and allows entry of the fluorescent dye SYTOX green 26 Hexima Limited ©
Slide 27: NaD1 Defensin Enters Live Fungal Cells
NaD1 Defensin Enters Live Fungal Cells Fluorescently tagged defensin N C 10 min 27 Hexima Limited ©
Slide 28: After NaD1 Entry the Fungal Cells Die
After NaD1 Entry the Fungal Cells Die Granular contents 3h 28 Hexima Limited ©
Slide 29: The Defensin Team
The Defensin Team 29 Hexima Limited ©
Slide 30: Hexima's Transformation Capabilities
Annual General Meeting 25th November 2008 Dr Robyn Heath Senior Vice President Product Development “Hexima’s Transformation Capabilities”
Slide 31: Hexima's Crop Modification Capabilities
Hexima’s Crop Modification Capabilities Canola Cotton Corn 31 Hexima Limited ©
Slide 32: Tissue Culture Facilities
Tissue Culture Facilities Sterile hoods New canola/corn growth room Cotton growth room 32 Hexima Limited ©
Slide 33: Glasshouse Facilities
Glasshouse Facilities Quarantine glasshouse, La Trobe University The University of Melbourne Plan for new Hexima glasshouse and tissue culture facility 33 Hexima Limited ©
Slide 34: Process for Transferring a New Gene Into a Plant
Process for Transferring a New Gene Into a Plant (Transformation) DNA insertion Cell division New gene Plant cell Plant regeneration Transgenic plant in tissue culture 34 Hexima Limited ©
Slide 35: Transformation of Cotton
Transformation of Cotton Seedlings Hypocotyl segment + DNA Callus developing Plant developing Transgenic plant 35 Hexima Limited ©
Slide 36: Transformed Plants Grown in the Glasshouse
Transformed Plants Grown in the Glasshouse Plantlets transferred to soil Checking phenotype in the glasshouse 36 Hexima Limited ©
Slide 37: Fungal Bioassays With Transformed Cotton
Fungal Bioassays With Transformed Cotton Wilt symptoms caused by Fusarium oxysporum (Fusarium wilt) Collecting data 37 Hexima Limited ©
Slide 38: Fungal Resistance Field Trial 2006/2007
Fungal Resistance Field Trial 2006/2007 Conventional Transgenic Conventional 38 Hexima Limited ©
Slide 39: Hexima's Crop Modification Capabilities
Hexima’s Crop Modification Capabilities Canola Cotton Corn 39 Hexima Limited ©
Slide 40: Annual General Meeting - Deputy Chairman
Annual General Meeting 25th November 2008 Professor Adrienne Clarke Deputy Chairman